Science 37 Enrolls 42% of Trial Cohort in 8 Weeks
July 18 2024 - 8:00AM
Science 37, a leader in enhancing patient access to clinical
trials, disclosed the final figures resulting from its partnership
with a biopharmaceutical company focused on infectious disease
prevention research. Science 37 contributed to the recruitment and
enrollment of an immunocompromised patient cohort for the sponsor’s
Phase 3 trial.
Leveraging its proprietary Virtual Site and Patient Recruitment
solutions, Science 37 identified, recruited, medically qualified,
and enrolled 129 patients across 36 states within an 8-week
timeline, averaging 65 patients per month. As the top-enrolling
site, Science 37 successfully randomized and treated 42% of the
cohort while achieving significant geographic, socio-economic, and
cultural diversity among participants.
"Depending on the rarity of the condition or sensitivities of
the target patient population, some studies are inherently more
difficult to recruit and enroll," said Dr. Debra Weinstein, VP of
Internal Medicine and Principal Investigator at Science 37. “The
complex nature of this study underscores Science 37’s ability to
meet challenging clinical trial demands while enhancing patient
access and care for vulnerable populations in a fully decentralized
manner.”
Science 37’s Patient Recruitment is available on a standalone
basis to clinical research sponsors and CROs looking to enhance
their patient enrollment efforts, or in combination with Science
37’s industry-leading flagship Virtual Site, the Metasite™, as part
of an accelerated patient access offering. For more information,
please visit www.science37.com.
About Science 37
Science 37’s mission is to accelerate clinical research by
enabling universal trial access for patients. Through our
solutions; the Metasite™ and Patient Recruitment, we accelerate
enrollment by expanding the reach of clinical trials to patients
beyond the traditional site and rigorously qualifying patients
prior to referring them to a traditional site. Our solutions are
powered by a proprietary technology stack with in-house medical and
operational experts that enhance quality through standardized
workflows and best-in-class study orchestration. To learn more,
visit www.science37.com, or email science37@science37.com.
To view studies that Science 37 is actively recruiting for,
please visit https://studies.science37.com/current-studies.
Media Inquiries
Science 37PR@science37.com
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Dec 2024 to Jan 2025
Science 37 (NASDAQ:SNCE)
Historical Stock Chart
From Jan 2024 to Jan 2025